Inhalational system for Etoposide liposomes: formulation development and in vitro deposition

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Nanotechnology

Background:

• Etoposide is a key chemotherapy agent for non-small cell lung cancer.
• Frequent dosing and adverse effects limit etoposide efficacy.
• Liposomal systems are promising for pulmonary drug delivery due to lung surfactant compatibility.

Purpose of the Study:

• To develop and characterize a liposomal pulmonary delivery system for etoposide.
• To optimize liposome formulation for enhanced entrapment efficiency and particle size.
• To improve the shelf-life and stability of etoposide liposomes through freeze-drying.

Main Methods:

• Liposomes prepared using the film hydration method.
• Formulation optimization for entrapment efficiency and particle size.
• Freeze-drying with trehalose as a cryoprotectant for enhanced stability.
• Characterization included entrapment efficiency, particle size, surface topography, and in vitro drug release.
• Fine particle fraction assessed using a twin-stage impinger.

Main Results:

• Optimized etoposide liposomes were successfully prepared.
• Freeze-dried liposomes demonstrated superior fine particle fraction and drug content.
• Stability studies showed freeze-dried liposomes maintained integrity over six months at various temperatures.
• In vitro release studies were conducted in simulated lung fluid at 37°C, pH 7.4.

Conclusions:

• Freeze-dried liposomal etoposide offers a stable and effective pulmonary delivery system.
• This approach can potentially improve lung cancer treatment by optimizing etoposide administration.
• The enhanced stability and respirable characteristics address limitations of conventional etoposide therapy.